antineoplaston therapy in treating patients with recurrent or refractory oligodendroglioma

Conditions: Oligodendroglioma, Adult

Summary: rationale: current therapies for adult recurrent/progressive oligodendrogliomas provide very limited benefit to the patient. the anti-cancer properties of antineoplaston therapy suggest that it may prove beneficial in the treatment of childhood brain tumors. purpose: this study is being performed to determine the effects (good and bad) that antineoplaston therapy has on adult recurrent/progressive oligodendrogliomas.

overview: this is a single arm, open-label study in which adults with recurrent/progressive oligodendrogliomas receive gradually escalating doses of intravenous antineoplaston therapy (atengenal + astugenal) until the maximum tolerated dose is reached. treatment continues for at least 12 months in the absence of disease progression or unacceptable toxicity. objectives: * to determine the efficacy of antineoplaston therapy in adults with recurrent/progressive oligodendrogliomas, as measured by an objective response to therapy (complete response, partial response or stable disease). * to determine the safety and tolerance of antineoplaston therapy in adults with recurrent/progressive oligodendrogliomas. * to determine objective response, tumor size is measured utilizing mri scans, which are performed every 8 weeks for the first two years, every 3 months for the third and fourth years, every 6 months for the 5th and sixth years, and annually thereafter. projected accrual: a total of 20-40 patients will be accrued to this study.

Eligibility criteria:
disease characteristics: * histologically or cytologically confirmed incurable oligodendroglioma that progressed during or is recurrent or residual after initial therapy, including radiotherapy and/or chemotherapy * measurable tumor by mri scan performed within two weeks prior to study entry * tumor must be at least 5 mm * no brain stem tumors patient characteristics: age: * 18 and over performance status: * karnofsky 60-100% life expectancy: * at least 2 months hematopoietic: * wbc at least 2,000/mm\^3 * platelet count at least 50,000/mm\^3 hepatic: * bilirubin no greater than 2.5 mg/dl * sgot/sgpt no greater than 5 times upper limit of normal * no hepatic failure renal: * creatinine no greater than 2.5 mg/dl * no history of renal conditions that contraindicate high dosages of sodium cardiovascular: * no severe heart disease * no uncontrolled hypertension * no history of congestive heart failure * no history of other cardiovascular conditions that contraindicate high dosages of sodium pulmonary: * no severe lung disease (e.g., chronic obstructive pulmonary disease) other: * not pregnant or nursing * fertile patients must use effective contraception during and for 4 weeks after study participation * no serious active infections * no other serious concurrent disease prior concurrent therapy: biologic therapy: * see disease characteristics * at least 4 weeks since prior immunotherapy chemotherapy: * see disease characteristics * at least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) endocrine therapy: * concurrent corticosteroids allowed radiotherapy: * see disease characteristics * at least 8 weeks since prior radiotherapy surgery: * recovered from any prior surgery other: * no prior antineoplaston therapy

Keywords: recurrent/progressive adult oligodendroglioma recurrent/progressive adult anaplastic oligodendroglioma